# Inhibrx Biosciences, Inc.: financial statements, quarterly

INBX · Nasdaq · CIK 2007919 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inbx.md) · [Financials](/companies/inbx/financials.md) · [Filings](/companies/inbx/filings.md) · [Insiders](/companies/inbx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inbx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0002007919-24-000058.md) | [1.6 d](/filings/0002007919-25-000019.md) | [0.0](/filings/0002007919-25-000056.md) | [0.1](/filings/0002007919-25-000081.md) | [0.0](/filings/0002007919-25-000093.md) | [0.1 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-25-000056.md) | [1.3](/filings/0002007919-26-000042.md) | [0.0](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | not reported | [0.0](/filings/0002007919-26-000042.md) |
| Research and development | $m | [38.1](/filings/0002007919-24-000058.md) | [82.1 d](/filings/0002007919-25-000019.md) | [63.9](/filings/0002007919-25-000056.md) | [67.6](/filings/0002007919-25-000081.md) | [38.9](/filings/0002007919-25-000093.md) | [33.4 d](/filings/0002007919-26-000006.md) | [36.9](/filings/0002007919-26-000027.md) | [22.3](/filings/0002007919-26-000042.md) | [28.5](/filings/0002007919-25-000093.md) | [25.3 d](/filings/0002007919-26-000006.md) | [25.2](/filings/0002007919-26-000027.md) | [23.9](/filings/0002007919-26-000042.md) |
| Operating income | $m | [(45.8)](/filings/0002007919-24-000058.md) | [(88.3) d](/filings/0002007919-25-000019.md) | [(73.8)](/filings/0002007919-25-000056.md) | [(161)](/filings/0002007919-25-000081.md) | [(46.8)](/filings/0002007919-25-000093.md) | [(49.9) d](/filings/0002007919-26-000006.md) | [(42.9)](/filings/0002007919-26-000027.md) | [(27.4)](/filings/0002007919-26-000042.md) | [(33.8)](/filings/0002007919-25-000093.md) | [(30.9) d](/filings/0002007919-26-000006.md) | [(30.9)](/filings/0002007919-26-000027.md) | [(32.1)](/filings/0002007919-26-000042.md) |
| Interest expense | $m | [8.1](/filings/0002007919-24-000058.md) | [8.2 d](/filings/0002007919-25-000019.md) | [8.1](/filings/0002007919-25-000056.md) | [5.4](/filings/0002007919-25-000081.md) | [0.0](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | [2.7](/filings/0002007919-26-000027.md) | [3.1](/filings/0002007919-26-000042.md) | [3.2](/filings/0002007919-25-000093.md) | [3.2 d](/filings/0002007919-26-000006.md) | [3.5](/filings/0002007919-26-000027.md) | [5.7](/filings/0002007919-26-000042.md) |
| Income tax | $m | [0.0](/filings/0002007919-24-000058.md) | [(0.0) d](/filings/0002007919-25-000019.md) | [0.0](/filings/0002007919-25-000056.md) | [0.0](/filings/0002007919-25-000081.md) | [0.0](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-26-000027.md) | [0.0](/filings/0002007919-26-000042.md) | [0.0](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-26-000027.md) | [0.0](/filings/0002007919-26-000042.md) |
| Net income | $m | [(51.8)](/filings/0002007919-24-000058.md) | [(93.6) d](/filings/0002007919-25-000019.md) | [(78.7)](/filings/0002007919-25-000093.md) | [1,858](/filings/0002007919-25-000093.md) | [(43.9)](/filings/0002007919-25-000093.md) | [(47.9) d](/filings/0002007919-26-000006.md) | [(43.3)](/filings/0002007919-26-000042.md) | [(28.7)](/filings/0002007919-26-000042.md) | [(35.3)](/filings/0002007919-25-000093.md) | [(32.8) d](/filings/0002007919-26-000006.md) | [(33.4)](/filings/0002007919-26-000042.md) | [(36.7)](/filings/0002007919-26-000042.md) |
| Diluted EPS | $ per share | [(4.39)](/filings/0002007919-24-000058.md) | not reported | [(5.77)](/filings/0002007919-25-000056.md) | [125.48](/filings/0002007919-25-000081.md) | [(2.84)](/filings/0002007919-25-000093.md) | not reported | [(2.80)](/filings/0002007919-26-000027.md) | [(1.85)](/filings/0002007919-26-000042.md) | [(2.28)](/filings/0002007919-25-000093.md) | not reported | [(2.15)](/filings/0002007919-26-000027.md) | [(2.34)](/filings/0002007919-26-000042.md) |
| Basic EPS | $ per share | [(4.39)](/filings/0002007919-24-000058.md) | not reported | [(5.77)](/filings/0002007919-25-000056.md) | [127.10](/filings/0002007919-25-000081.md) | [(2.84)](/filings/0002007919-25-000093.md) | not reported | [(2.80)](/filings/0002007919-26-000027.md) | [(1.85)](/filings/0002007919-26-000042.md) | [(2.28)](/filings/0002007919-25-000093.md) | not reported | [(2.15)](/filings/0002007919-26-000027.md) | [(2.34)](/filings/0002007919-26-000042.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [278](/filings/0002007919-25-000019.md) | not reported | [227](/filings/0002007919-24-000029.md) | [196](/filings/0002007919-24-000058.md) | [153](/filings/0002007919-26-000006.md) | [217](/filings/0002007919-25-000056.md) | [187](/filings/0002007919-25-000081.md) | [153](/filings/0002007919-25-000093.md) | [124](/filings/0002007919-26-000042.md) | [162](/filings/0002007919-26-000027.md) | [133](/filings/0002007919-26-000042.md) |
| Current assets | $m | not reported | [295](/filings/0002007919-25-000019.md) | not reported | [242](/filings/0002007919-24-000029.md) | [207](/filings/0002007919-24-000058.md) | [160](/filings/0002007919-26-000006.md) | [223](/filings/0002007919-25-000056.md) | [194](/filings/0002007919-25-000081.md) | [161](/filings/0002007919-25-000093.md) | [133](/filings/0002007919-26-000042.md) | [171](/filings/0002007919-26-000027.md) | [142](/filings/0002007919-26-000042.md) |
| Total assets | $m | not reported | [308](/filings/0002007919-25-000019.md) | not reported | [258](/filings/0002007919-24-000029.md) | [223](/filings/0002007919-24-000058.md) | [181](/filings/0002007919-26-000006.md) | [243](/filings/0002007919-25-000056.md) | [212](/filings/0002007919-25-000081.md) | [177](/filings/0002007919-25-000093.md) | [146](/filings/0002007919-26-000042.md) | [184](/filings/0002007919-26-000027.md) | [154](/filings/0002007919-26-000042.md) |
| Current liabilities | $m | not reported | [56.3](/filings/0002007919-25-000019.md) | not reported | [39.1](/filings/0002007919-24-000029.md) | [44.1](/filings/0002007919-24-000058.md) | [40.7](/filings/0002007919-26-000006.md) | [43.6](/filings/0002007919-25-000056.md) | [38.9](/filings/0002007919-25-000081.md) | [36.0](/filings/0002007919-25-000093.md) | [33.8](/filings/0002007919-26-000042.md) | [26.5](/filings/0002007919-26-000027.md) | [28.1](/filings/0002007919-26-000042.md) |
| Total liabilities | $m | not reported | [264](/filings/0002007919-25-000019.md) | not reported | [39.1](/filings/0002007919-24-000029.md) | [44.1](/filings/0002007919-24-000058.md) | [47.2](/filings/0002007919-26-000006.md) | [148](/filings/0002007919-25-000056.md) | [144](/filings/0002007919-25-000081.md) | [141](/filings/0002007919-25-000093.md) | [138](/filings/0002007919-26-000042.md) | [205](/filings/0002007919-26-000027.md) | [207](/filings/0002007919-26-000042.md) |
| Long-term debt | $m | not reported | [207](/filings/0002007919-25-000019.md) | not reported | [0.0](/filings/0002007919-24-000029.md) | [0.0](/filings/0002007919-24-000058.md) | [0.0](/filings/0002007919-26-000006.md) | [98.7](/filings/0002007919-25-000056.md) | [99.3](/filings/0002007919-25-000081.md) | [99.9](/filings/0002007919-25-000093.md) | [101](/filings/0002007919-26-000042.md) | [175](/filings/0002007919-26-000027.md) | [176](/filings/0002007919-26-000042.md) |
| Shareholders' equity | $m | [130](/filings/0002007919-24-000058.md) | [43.5](/filings/0002007919-26-000006.md) | [11.6](/filings/0002007919-25-000093.md) | [219](/filings/0002007919-25-000093.md) | [178](/filings/0002007919-25-000093.md) | [134](/filings/0002007919-26-000042.md) | [94.4](/filings/0002007919-26-000042.md) | [68.6](/filings/0002007919-26-000042.md) | [36.8](/filings/0002007919-25-000093.md) | [8.0](/filings/0002007919-26-000042.md) | [(21.0)](/filings/0002007919-26-000042.md) | [(53.0)](/filings/0002007919-26-000042.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(54.2) d](/filings/0002007919-24-000058.md) | [(56.8) d](/filings/0002007919-25-000019.md) | [(63.1)](/filings/0002007919-25-000056.md) | [(57.4) d](/filings/0002007919-25-000081.md) | [(30.3) d](/filings/0002007919-25-000093.md) | [(43.7) d](/filings/0002007919-26-000006.md) | [(35.9)](/filings/0002007919-26-000027.md) | [(30.0) d](/filings/0002007919-26-000042.md) | [(33.8) d](/filings/0002007919-25-000093.md) | [(30.1) d](/filings/0002007919-26-000006.md) | [(38.0)](/filings/0002007919-26-000027.md) | [(29.9) d](/filings/0002007919-26-000042.md) |
| Capital expenditure | $m | [0.8 d](/filings/0002007919-24-000058.md) | [3.4 d](/filings/0002007919-25-000019.md) | [1.1](/filings/0002007919-25-000056.md) | [1.2 d](/filings/0002007919-25-000081.md) | [0.2 d](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-26-000027.md) | [0.0 d](/filings/0002007919-26-000042.md) | [0.0 d](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-26-000027.md) | [0.0 d](/filings/0002007919-26-000042.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.9](/filings/0002007919-24-000029.md) | [11.8](/filings/0002007919-24-000058.md) | [13.6](/filings/0002007919-25-000056.md) | [14.8](/filings/0002007919-25-000081.md) | [15.5](/filings/0002007919-25-000093.md) | [15.5](/filings/0002007919-26-000027.md) | [15.5](/filings/0002007919-26-000042.md) | [15.5](/filings/0002007919-25-000093.md) | [15.6](/filings/0002007919-26-000027.md) | [15.7](/filings/0002007919-26-000042.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,717,660 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0002007919-26-000042.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.